Rapport Therapeutics officer proposes $1.23M sale

The shares listed for sale were acquired as compensation through performance awards on December 2, 2022.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) lists a proposed sale by its Officer, Abraham N. Ceesay, of 39,470 common shares, with an aggregate market value of $1,229,490.50. Goldman Sachs & Co. LLC is listed as the broker, and October 6, 2026, as the approximate sale date. The notice connects the sale to a selling plan dated March 27, 2026, intended to comply with Rule 10b5-1(c). It also lists prior sales by Ceesay during the preceding three months, including 22,541 shares on August 10, 2026, 28,958 shares on August 11, 2026, and 8,501 shares on August 25, 2026.

Key Figures

Proposed common shares: 39,470 shares Aggregate market value: $1,229,490.50 Approximate sale date: October 6, 2026 +3 more

6 metrics

Proposed common shares 39,470 shares Proposed sale by Abraham N. Ceesay

Aggregate market value $1,229,490.50 Proposed sale

Approximate sale date October 6, 2026 Proposed sale

Prior shares sold 22,541 shares August 10, 2026

Prior shares sold 28,958 shares August 11, 2026

Prior shares sold 8,501 shares August 25, 2026

Key Terms

aggregate market value, Rule 10b5-1(c), performance awards

3 terms

aggregate market value financial

"with an aggregate market value of $1,229,490.50"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

performance awards financial

"acquired as compensation through performance awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RAPP shares does Abraham N. Ceesay propose to sell?

The proposed sale covers 39,470 common shares, with an aggregate market value of $1,229,490.50. The approximate sale date is October 6, 2026.

How did Abraham N. Ceesay acquire the RAPP shares listed for sale?

The shares were acquired as compensation through performance awards on December 2, 2022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 06:19 PM Accepted by SEC EDGAR 10/06/2026 - 06:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001722140
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RAPPORT THERAPEUTICS, INC.
SEC File Number	001-42121
Address of Issuer	99 High Street Suite 2100 Boston MASSACHUSETTS 02110
Phone	1-857-321-8020
Name of Person for Whose Account the Securities are To Be Sold	Abraham N. Ceesay
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	39470	1229490.5	47978286	10/06/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/02/2022	Acquired as compensation -- Performance Awards	Issuer			39470	12/02/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	07/14/2026	6000	241228.2
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	07/14/2026	2210	87208.37
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	09/08/2026	2210	99907.47
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	09/23/2026	2210	86565.04
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	07/27/2026	2210	93060.89
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	09/08/2026	6000	274590.6
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	08/25/2026	4420	217996.17
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	08/10/2026	22541	1042771.46
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	08/11/2026	28958	1390403.89
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	08/25/2026	8501	422764.08
Abraham N. Ceesay 99 High Street Suite 2100 Boston MA 02110	Common	08/25/2026	6000	297198

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 03/27/2026, that is intended to comply with Rule 10b5-1(c).
Date of Notice	10/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Abraham N. Ceesay
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)